The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
The effects of treatment by immunotherapy and chemoimmunotherapy were assessed in 31 non-randomized patients with melanoma; 16 received only BCG and 15 BCG and chemotherapy. For advanced cases, the times of survival for the two treatment groups did not differ significantly, nor did there appear to be any improvement in survival over that recorded for the natural course of the disease. The pretreatment immune status as judged by hyporeactivity or normal reactivity to skin tests for delayed type hypersensitivity did not appear to influence survival. This study, together with other reports, does not support the use of immunotherapy in advanced melanoma. Immunotherapy for early melanoma is still to be assessed.
D001500:BCG Vaccine / Q000627:therapeutic use*; D003606:Dacarbazine / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007111:Immunity, Cellular; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D009607:Nitrosourea Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D012882:Skin Tests; D013997:Time Factors; D014226:Triazenes / Q000008:administration & dosage*
D001500:BCG Vaccine; D009607:Nitrosourea Compounds; D014226:Triazenes; D003606:Dacarbazine; D006918:Hydroxyurea